• Achieved nationwide distribution of Vamousse Lice Treatment with Walmart
in the USA, as well as with Amazon.com, Walmart.com and Drugstore.com
• Expanded distribution of Vamousse Lice Treatment in the USA with
McKesson, and independent pharmacy retailers, including Rochester Drug,
Lewis Drug and Bartell Drug
• Guardian personal mosquito and tick repellent available online with
Amazon.com in the USA
• Established a UK branch and engaged specialist healthcare marketing firm
to handle all marketing, commercialisation and logistics in the UK
• Launched Vamousse Lice Treatment in Boots and Tesco stores and in
Superdrug, Rowlands and Sainsbury's stores, where we also launched
Vamousse Lice Protection Shampoo in the UK
• Received nine new patents from the United States and international patent
offices for the Company's novel pest control compositions
• Overall gross revenue for 2014 was $4.9 million, a 250 percent year-over-year
increase
• Total gross product revenue in initial product launch year was $2.8 million
• Overall gross margin was 74.9 percent
• Product gross margin was 64.1 percent
• Operating expenses of $8.5 million reflect product launch activities in both
the USA and UK
• Net loss, before and after taxes, was $5.1 million
• Cash and cash equivalents at 31 December 2014 were $2.2 million
• Received $8.9 million in net proceeds from stock issuances
TYRATECH • ANNUAL REPORT 2014 • PAGE 1
H i g h l i g h t s a n d A c c o m p l i s h m e n t s
Fi n a n c i a l H i g h l i g h t s
